GW Pharmaceuticals announced the approval of EPIDIOLEX® (cannabidiol) oral solution as the first plant-derived cannabinoid prescription medication.
Browsing: antiepileptic drugs
Polymorphisms in ABCB1 and EPHX1 genes influence drug effectiveness in refractory epilepsy: a retrospective study
This communication examines the association between the number of seizures in refractory epileptic patients and potential interactions between their antiepileptic medications and single nucleotide polymorphisms.
Research demonstrates a daily dose of cannabidiol may help reduce seizures in children and adults suffering from Lennox- Gastaut syndrome (LGS).
Influence of acylpeptide hydrolase polymorphisms on valproic acid level in Chinese epilepsy patients
In this research article, the authors determine the the effect of APEH polymorphism on VPA pharmacokinetics in the Chinese population.
Better prognosis for glioblastoma patients with seizures has raised questions about the anti-tumor properties of antiepileptic drugs. This article reviews the potential mechanisms associated with this.
Redesign of retigabine could improve potency, specificity and side effects of the drug.
Approval of brivaracetam (BRIVIACT®) as an adjunctive therapy in the treatment of partial-onset seizures in epilepsy patients aged 16 years and older announced by the US-FDA.
We discuss some of the key research themes that emerged from the American Epilepsy Society’s (AES) Annual Meeting this year.
We get an overview of the results of the perampanel trials from the American Epilepsy Society Annual Meeting (4–8 December 2015, Philadelphia, PA) from Eugen Trinka (Paracelsus Medical University, Salzburg, Austria).
Results from the EPOS study suggest efficacy of eslicarbazepine acetate as add-on therapy to anti-epileptic monotherapy in real-world setting.